Jonathan Spicer MD PhD
@DoctorJSpicer
Medical Director of the McGill Thoracic Oncology Program; Chest surgeon; Neutrophil biologist; Cancer immunologist; Aspiring farmer
KN671 OS and HRQoL! Check it out: sciencedirect.com/science/articl…
NCDB study of pts who survive >5 years in 🫁mesothelioma. ➡️Overall 9.4% of MPM pts, many without surgical resection. Pts who are offered surgery and DECLINE have same survival as those who undergo surgery. Real world KM curves look just like MARS2. sciencedirect.com/science/articl…
So excited to see this paper on the stromal changes driving Barrett’s Esophagus progression to Cancer. A Herculean effort effort integrating scRNASeq/CODEX/ECM proteomics. Concerted changes in Epithelium and Stroma: a multi-scale, multi-omics... sciencedirect.com/science/articl…
Posted this now @biorxivpreprint ! A comprehensive effort from @mcgillu detailing progressive refinement of gastroesophageal adenocarcinoma patient-derived #organoid generation. A huge bio repository of almost 400 patient tumours! @organoidscience biorxiv.org/content/10.110…
I’m happy to share our latest work on tumour necrosis! During my time in the @megeblad lab, we found that tumour necrosis is not a passive phenomenon secondary to tumour growth, but an active phenomenon driven by neutrophils and NETs! Thread below: (1/13) nature.com/articles/s4158…
🧠 Trained immunity may worsen lung inflammation, according to new research from The Institute. When immune memory goes too far, it can cause harm. 🔗 rimuhc.ca/en/-/study-rev… @cusm_muhc @mcgillu
Understanding and reversing mammary tumor-driven reprogramming of myelopoiesis to reduce metastatic spread dlvr.it/TLx7DZ
A study led by Josie Ursini-Siegel of the Lady Davis Institute for Medical Research at the Jewish General Hospital has identified a novel approach to combat aggressive breast cancers by retraining neutrophils to directly kill tumour cells. bit.ly/3TCpsgg #cancerresearch
AUDIOBOOK JUST RELEASED @GooglePlay What is it like to treat patients and develop a cutting edge research program at a major cancer center? Hear the stories about those who helped or hindered these efforts along with an inside look at the politics of cancer research and treatment…
🇸🇦-🇨🇦 Please join us Masterclass organized by the Canadian Association of Thoracic Surgeons is directed by @moisheliberman will take place at CHUM - Centre hospitalier de l'Université de Montréal as part of the activities of the Canadian Surgery Forum 2025
Medical Oncology #fellowship program is open again!! Apply if interested as the applications are open @mcgillu @McGillMed @RIMUHC1 @cusm_muhc @McgillGBDO lnkd.in/eN4vhanj
Happy to share our recent paper in @eLife showing the detrimental effects of β-Glucan in a murine LPS-model of lung injury This study was led by Renaud from @chubordeauxfr and incredible collaborators @erwan_pernet @kimaimytran Dr Poschmann @NantesUniv doi.org/10.7554/eLife.…
🚨 Just published! TP53 co-mutations significantly increase the risk of recurrence in stage I EGFR-mutated LUAD. 🔬 Worse RFS, similar OS → supports the need for treatment escalation even in early-stage disease. sciencedirect.com/science/articl…
Thanks to all the @mcgillu family for support @LFerri123 @sara_najmeh @JonathanCools @ronirayes and @DoctorJSpicer for his guidance and mentorship!
🚨 JAMA 2025 Real world reckoning in resectable NSCLC: • Neoadjuvant IO usage: 13.8% • Adjuvant IO: 22.6% • PD-L1 untested: 47% • EGFR/ALK untested: 50% Treatment exists but testing, selection, and uptake don’t follow. #LCSM #NSCLC @OncoAlert 🔗 jamanetwork.com/journals/jaman…
This @KGMitchellMD study shows ⬆️ circulating neutrophil-to-lymphocytes (cNLR) reflects ⬆️ tumor NLR (tNLR), ⬆️ tNLR is associated with immunosuppressive/pro-tumor TME, and tNLR is a stronger negative prognosticator than cNLR in resectable NSCLC. #oncsurg jitc.bmj.com/content/13/6/e…
Online Now: Chemotherapy awakens dormant cancer cells in lung by inducing neutrophil extracellular traps dlvr.it/TLjsMp
Now published & open soon in 🇮🇪 Trial in progress that will answer q of neoadj only vs. periop immunotherapy for lung cancer! ETOP 25-23 ADOPT-lung: Phase III trial to evaluate adj durvalumab after neoadj chemo plus durva in pts w resectable NSCLC. #lcsm lungcancerjournal.info/article/S0169-…